Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Demetriou, Victoria L ^a   van de Vijver, David A M C ^b   Kousiappa, Ioanna ^a   Balotta, Claudia ^c   Clotet, Bonaventura ^d   Grossman, Zehava ^e   Jørgensen, Louise B ^f   Lepej, Snjezana Z ^g   Levy, Itzchak ^e   Nielsen, Claus ^f   Paraskevis, Dimitrios ^h   Poljak, Mario ⁱ   Roman, Francois ^j   Ruiz, Lidia ^d   Schmidt, Jean Claude ^j   Vandamme, Anne Mieke ^k   van Laethem, Kristel ^k   Vercauteren, Jurgen ^k   Kostrikis, Leondios G ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e SHEBA MEDICAL CENTER   (Israel)

^f STATENS SERUM INSTITUT   (Denmark)

^g Croatia   (Croatia)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^k REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DOUBLE STRANDED DNA; GENOMIC DNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE INHIBITOR; VIRUS RNA; PRIMER DNA; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EUROPE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; MALE; MOLECULAR BEACON; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS LOAD; ALLELE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; VIRAL TROPISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ALLELES; BASE SEQUENCE; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; SEQUENCE HOMOLOGY, NUCLEIC ACID; VIRAL LOAD; VIRAL TROPISM;

EID: 77956214553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010976     Document Type: Article

References (54)

1. SPREAD programme (2008) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22: 625-635.
2. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, et al. (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187: 683-686.
3. Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, et al. (2004) Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. Aids 18: 2185-2189.
4. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, et al. (2005) French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 38: 545-552.
5. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, et al. (2004) The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189: 2174-2180.
6. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
7. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, et al. (2008) Transmission networks of drug resistance acquired in primary/early stage HIV infection. Aids 22: 2509-2515.
8. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, et al. (2001) Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. Aids 15: 2287-2292.
9. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
10. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
11. Sedaghat AR, Siliciano RF, Wilke CO (2008) Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8: 2.
12. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195: 1762-1764.
13. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 100: 4819-4824.
14. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410-1418.
15. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
16. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53: 557-593.
17. Alexaki A, Liu Y, Wigdahl B (2008) Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 6: 388-400.
18. Pierson T, McArthur J, Siliciano RF (2000) Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18: 665-708.
19. Avettand-Fenoel V, Boufassa F, Galimand J, Meyer L, Rouzioux C (2008) HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 42: 399-404.
20. Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, et al. (2002) Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 76: 10099-10108.
21. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, et al. (2006) CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42: 709-715.
22. Ferre F, Moss RB, Daigle A, Richieri SP, Jensen F, et al. (1995) Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. J Acquir Immune Defic Syndr Hum Retrovirol 10: Suppl 2S 51-56.
23. Verhofstede C, Reniers S, Van Wanzeele F, Plum J (1994) Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. Aids 8: 1421-1427.
24. Russell RR, Bowmer MI, Nguyen C, Grant MD (2001) HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. Viral Immunol 14: 379-389.
25. Re MC, Vitone F, Bon I, Schiavone P, Gibellini D (2006) Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol 29: 81-88.
26. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, et al. (2002) Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 185: 1409-1416.
27. Hatzakis AE, Touloumi G, Pantazis N, Anastassopoulou CG, Katsarou O, et al. (2004) Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. Aids 18: 2261-2267.
28. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, et al. (2001) Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. Aids 15: 665-673.
29. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, et al. (2005) Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192: 46-55.
30. Tierney C, Lathey JL, Christopherson C, Bettendorf DM, D'Aquila RT, et al. (2003) Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 187: 144-148.
31. Re MC, Vitone F, Biagetti C, Schiavone P, Alessandrini F, et al. (2009) HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. Clin Microbiol Infect.
32. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, et al. (2004) Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. Aids 18: 45-49.
33. Beloukas A, Paraskevis D, Psichogiou M, Hatzakis A (2009) The role of HIV-1 DNA as an additional marker of HIV-1 infection. Curr HIV Res 7: 255-265.
34. Ruitenberg JJ, Mulder CB, Maino VC, Landay AL, Ghanekar SA (2006) VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol 7: 11.
35. Kousiappa I, van de Vijver DA, Demetriades I, Kostrikis LG (2009) Genetic analysis of HIV type 1 strains from newly infected untreated patients in Cyprus: high genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses 25: 23-35.
36. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
37. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
38. Kimura M (1980) A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16: 111-120.
39. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
40. Felsenstein J (1985) Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39: 783-791.
41. http://hivdb.stanford.edu (2009) Stanford HIV Resistance Database: Genotypic resistance interpretation algorithm (HIVdb Program: Sequence analysis)
42. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
43. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2008) Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 16: 138-145.
44. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106.
45. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI (2006) A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 80: 4698-4704.
46. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
47. Tyagi S, Kramer FR (1996) Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 14: 303-308.
48. Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6: 986-994.
49. Hatzakis A, Touloumi G, Karanicolas R, Karafoulidou A, Mandalaki T, et al. (2000) Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 355: 599-604.
50. Kabamba-Mukadi B, Henrivaux P, Ruelle J, Delferriere N, Bodeus M, et al. (2005) Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR. BMC Infect Dis 5: 15.
51. Minga AK, Anglaret X, d' Aquin Toni T, Chaix ML, Dohoun L, et al. (2008) HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr 48: 350-354.
52. Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, et al. (2007) Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 45: 1288-1297.
53. van de Vijver D, Wensing AM, Boucher C (2007) The Epidemiology of Transmission of Drug Resistant HIV-1;. Thomas Leitner T, Foley B, Hahn B, Marx P, McCutchan F, et al., editors: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. LA-UR 07-4826. 17-36.
54. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.